Gastric cancer and trastuzumab: first biologic therapy in gastric cancer-Reference-Cited by-同舟云学术

Gastric cancer and trastuzumab: first biologic therapy in gastric cancer

Published:2013-01-04 Issue:2 Volume:5 Page:143-151
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Gunturu Krishna S.¹,Woo Yanghee²,Beaubier Nike²,Remotti Helen E.²,Saif M. Wasif³

Affiliation:

1. Division of Hematology/Oncology, Tufts Medical Center, Boston, MA, USA

2. Columbia University College of Physicians and Surgeons and the Herbert Irving Cancer Center, New York, NY, USA

3. Department of Medicine and Cancer Center, Tufts Medical Center, 800 Washington Street Box 245, Boston, MA 02111, USA

Abstract

Gastric cancer remains difficult to cure and has a poor overall prognosis. Chemotherapy and multimodality therapy has shown some benefit in the treatment of gastric cancer. Current therapies for gastric cancer have their limitations; thus, we are in need of newer treatment options including targeted therapies. Here, we review the biologic therapy with trastuzumab in human epidermal growth factor receptor 2 (HER2)+ gastric cancer.

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1758834012469429

Reference34 articles.

1. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial

2. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

3. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

4. Targeting c-erbB2 and Other Receptors of the C-ErbB Family: Rationale and Clinical Applications

5. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review;Frontiers in Immunology;2024-08-27

2. Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review;Frontiers in Oncology;2024-08-22

3. Pembrolizumab in combination with trastuzumab for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer;Annals of Medicine & Surgery;2024-06-21

4. Characterization of gastric cancer-stimulated signaling pathways and function of CTGF in cancer-associated fibroblasts;Cell Communication and Signaling;2024-01-02

5. Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer;Laboratory Investigation;2024-01